Tirzepatide

Overview

Tirzepatide (LY3298176) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company [17]. It represents a novel approach to metabolic disease treatment by simultaneously engaging both incretin receptor pathways, distinguishing it from single-target GLP-1 receptor agonists such as semaglutide and liraglutide [17][18].

The molecule was approved by the U.S. Food and Drug Administration (FDA) under the brand name Mounjaro for the treatment of type 2 diabetes mellitus in May 2022, and under the brand name Zepbound for chronic weight management in adults with obesity (BMI >=30 kg/m2) or overweight (BMI >=27 kg/m2) with at least one weight-related comorbidity in November 2023 [9][10]. In December 2024, the FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, making it the first and only prescription medicine approved for this indication [14]. The European Medicines Agency (EMA) approved Mounjaro for type 2 diabetes in September 2023 and subsequently for chronic weight management in June 2024. In December 2025, the EMA's CHMP adopted a positive opinion recommending extension of the Mounjaro indication to include type 2 diabetes in adolescents and children from 10 years of age. These approvals were supported by the SURPASS program (type 2 diabetes) and the SURMOUNT program (obesity), collectively enrolling over 25,000 participants across more than 15 Phase 3 clinical trials.

Molecular Weight

~4813.45 g/mol

Molecular Formula

C225H348N48O68

Sequence

39-amino acid peptide based on native GIP; Aib at positions 2 and 13; C20 fatty diacid via linker at Lys20; C-terminal amide

Half-life

~5 days (plasma albumin binding >99%)

Routes Studied

Subcutaneous injection (once weekly)

Bioavailability

~80% (subcutaneous)

FDA Status

Approved: Mounjaro (T2D, May 2022), Zepbound (obesity, Nov 2023; OSA, Dec 2024)

EMA Status

Approved: Mounjaro (T2D, Sep 2023; obesity, Jun 2024; pediatric T2D age >=10, Dec 2025)

WADA Status

Not prohibited

Molecular Structure and Pharmacology

Peptide Architecture

Tirzepatide is a synthetic linear peptide comprising 39 amino acids with a molecular weight of approximately 4813.45 Da and the molecular formula C225H348N48O68 [18][19]. Its primary sequence is based on native human GIP but incorporates several critical modifications to enable dual receptor activity and extended duration of action:

• Positions 2 and 13: Alpha-aminoisobutyric acid (Aib) residues replace native amino acids. These non-coded residues protect surrounding peptide bonds against proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and other endopeptidases, substantially increasing metabolic stability [18].
• Position 20 (Lys20): A C20 eicosanedioic (fatty diacid) moiety is conjugated via a gamma-glutamic acid-containing linker with two 8-amino-3,6-dioxaoctanoic acid (AEEA) spacer units. This lipid modification enables high-affinity binding to serum albumin (>99% protein binding), extending the plasma half-life to approximately five days and permitting once-weekly subcutaneous administration [18][19].
• C-terminus: The terminal residue is amidated, which enhances peptide stability and receptor interactions.

The choice of a C20 fatty diacid (as opposed to the C18 diacid used in semaglutide) contributes to tirzepatide's distinct pharmacokinetic profile. Following subcutaneous injection, time to maximum plasma concentration ranges from 8 to 72 hours, with a mean absolute bioavailability of approximately 80%. Steady-state concentrations are achieved after four weeks of once-weekly dosing [18].

Receptor Pharmacology

Tirzepatide functions as an imbalanced and biased dual agonist of the GIP and GLP-1 receptors [18]. Characterization studies have demonstrated that:

• Tirzepatide binds the GIP receptor with affinity comparable to native GIP, acting as a full agonist at this receptor.
• Tirzepatide binds the GLP-1 receptor with approximately five-fold lower affinity compared to native GLP-1, functioning as a partial agonist with biased signaling that favors cAMP production over beta-arrestin recruitment [18].

This imbalanced pharmacology is considered an engineered feature rather than a limitation. The preferential GIP receptor engagement, combined with sufficient GLP-1 receptor activation, may explain tirzepatide's superior efficacy profile compared to selective GLP-1 receptor agonists [2][18]. Importantly, tirzepatide has negligible activity at the glucagon receptor, distinguishing it from emerging triple agonist candidates [18].

Mechanism of Action

Tirzepatide exerts its pharmacological effects through simultaneous activation of both GIP and GLP-1 receptors, which are expressed across multiple tissues including the pancreas, brain, gastrointestinal tract, adipose tissue, bone, and the cardiovascular system [17][19].

GLP-1 Receptor-Mediated Effects

GLP-1 receptor activation contributes to glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowing of gastric emptying, and reduction in appetite through central mechanisms in the hypothalamus and brainstem [17]. These effects are well-characterized from clinical experience with selective GLP-1 receptor agonists such as semaglutide and liraglutide.

GIP Receptor-Mediated Effects

GIP receptor activation provides complementary and potentially synergistic benefits. GIP potentiates glucose-dependent insulin secretion and, in preclinical models, has been shown to enhance lipid metabolism in adipose tissue, promote lipid storage, and improve insulin sensitivity [17][19]. GIP receptor signaling in the central nervous system may also contribute to appetite regulation and energy homeostasis. The additive effects of dual incretin pathway engagement likely underpin the greater glycemic and weight-loss efficacy observed with tirzepatide compared to selective GLP-1 receptor agonists [2][13].

Effects on Beta-Cell Function and Insulin Sensitivity

In a dedicated mechanistic study using hyperglycemic clamp techniques, tirzepatide improved both first- and second-phase insulin secretion and enhanced insulin sensitivity to a degree that appeared to exceed effects seen with GLP-1 receptor agonists alone [19]. The disposition index (a composite measure of beta-cell function adjusted for insulin sensitivity) improved significantly, suggesting that tirzepatide may help restore more physiological glucose homeostasis [19].

Effects on Energy Balance

Tirzepatide reduces body weight through multiple mechanisms: suppression of appetite and food intake via central pathways, delayed gastric emptying, and potentially enhanced energy expenditure through effects on adipose tissue metabolism [9][17]. The relative contribution of GIP versus GLP-1 receptor signaling to weight loss in humans remains an active area of investigation.

Pharmacokinetics

Absorption

Tirzepatide is administered by subcutaneous (SC) injection and exhibits an absolute bioavailability of approximately 80% [18]. Following a single SC dose, the time to maximum plasma concentration (Tmax) ranges from 8 to 72 hours, with a median of approximately 24 hours. Absorption is comparable across injection sites (abdomen, thigh, upper arm), though minor differences in rate but not extent have been observed [18].

Distribution

The apparent volume of distribution (Vd) is approximately 10.3 L, consistent with a peptide that distributes primarily in the plasma compartment and extracellular fluid with limited tissue penetration [18][19]. Protein binding exceeds 99%, driven predominantly by high-affinity non-covalent binding to serum albumin via the C20 eicosanedioic fatty diacid moiety conjugated at Lys20 [18]. This albumin sequestration serves as the primary mechanism for half-life extension and also creates a circulating depot that buffers plasma concentrations, contributing to the low peak-to-trough ratio observed with weekly dosing.

Metabolism and Elimination

Tirzepatide undergoes proteolytic cleavage of the peptide backbone and beta-oxidation of the C20 fatty acid moiety, analogous to other acylated peptide therapeutics [18]. No single cytochrome P450 enzyme plays a dominant role in its metabolism, and no active metabolites have been identified. Elimination occurs through both urinary and fecal routes as metabolized fragments; intact tirzepatide is not appreciably excreted in urine. The effective elimination half-life is approximately 5 days (approximately 120 hours), supporting once-weekly administration [18][19].

Steady State and PK Linearity

Steady-state plasma concentrations are achieved after approximately 4 weeks (four to five doses) of once-weekly administration [18]. Tirzepatide exhibits dose-proportional (linear) pharmacokinetics across the 0.5 mg to 15 mg dose range, with no evidence of time-dependent changes in clearance. The accumulation ratio at steady state is approximately 1.4-fold relative to a single dose.

Special Populations

• Renal impairment: Population PK analyses showed no clinically meaningful effect of mild, moderate, or severe renal impairment (eGFR 15-89 mL/min/1.73m2) on tirzepatide exposure. No dose adjustment is required. Tirzepatide has not been studied in patients on dialysis [21][24].
• Hepatic impairment: No clinically significant effect of mild to moderate hepatic impairment on pharmacokinetics. Data in severe hepatic impairment are limited.
• Age, sex, race, and body weight: Population PK analyses across the SURPASS and SURMOUNT programs (encompassing diverse global populations) demonstrated no clinically relevant effects of age (18-85 years), sex, race, or ethnicity on tirzepatide exposure. Higher body weight is associated with modestly lower weight-adjusted exposure, but no dose adjustment is recommended based on body weight alone.
• Gastric emptying interaction: Tirzepatide slows gastric emptying, which can affect absorption kinetics of co-administered oral medications. This effect is most pronounced during dose escalation and attenuates at steady state. For oral contraceptives, the prescribing information recommends transitioning to a non-oral method or adding a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation step.

Dose-Response Relationships

Weight Loss by Dose (SURMOUNT Program)

Tirzepatide exhibits a clear dose-response relationship for weight reduction across all studied populations. In the pivotal SURMOUNT-1 trial in adults without diabetes [9]:

• 5 mg: -15.0% mean body weight reduction (vs -3.1% placebo)
• 10 mg: -19.5% mean body weight reduction
• 15 mg: -20.9% mean body weight reduction

The dose-response curve shows a steeper increment from 5 mg to 10 mg (approximately 4.5 percentage points additional weight loss) than from 10 mg to 15 mg (approximately 1.4 percentage points), suggesting a partial plateau effect approaching the highest dose [9]. In SURMOUNT-2 (adults with obesity and type 2 diabetes), the dose-response was attenuated compared to the non-diabetic population (10 mg: -12.8%; 15 mg: -14.7% vs -3.2% placebo), consistent with the known resistance to weight loss in type 2 diabetes [10].

HbA1c Reduction by Dose (SURPASS Program)

Glycemic dose-response across SURPASS trials:

• SURPASS-1: 5 mg: -1.87%, 10 mg: -1.89%, 15 mg: -2.07% [1]
• SURPASS-2: 5 mg: -2.01%, 10 mg: -2.24%, 15 mg: -2.30% [2]
• SURPASS-3: 5 mg: -1.93%, 10 mg: -2.20%, 15 mg: -2.37% [3]

HbA1c reductions show a dose-response relationship, though the incremental benefit from 10 mg to 15 mg is smaller than from 5 mg to 10 mg, indicating diminishing marginal glycemic returns at higher doses. Even the 5 mg dose achieves clinically meaningful HbA1c reductions exceeding those of most comparators studied.

Plateau Effects and Clinical Implications

The flattening of the dose-response curve at higher doses suggests that the maximum pharmacological effect for both weight and glycemic endpoints is being approached within the 10-15 mg dose range. This has clinical relevance: many patients may achieve adequate responses at 10 mg without requiring escalation to 15 mg, particularly if tolerability is a concern.

Dose Escalation and GI Tolerability

The 2.5 mg increment, 4-week interval dose-escalation schedule was specifically designed to mitigate gastrointestinal tolerability concerns [9]. Nausea, vomiting, and diarrhea are predominantly associated with dose initiation and escalation phases. In clinical trials, the gradual titration protocol reduced the incidence of severe GI events to approximately 1.7% (5 mg), 2.5% (10 mg), and 3.1% (15 mg) compared to higher rates observed with more rapid titration in earlier-phase studies [9]. Slower or paused escalation may be appropriate for patients experiencing significant GI symptoms, as most events are transient and self-limiting.

Comparative Effectiveness

Tirzepatide vs Semaglutide 2.4 mg (Head-to-Head: SURMOUNT-5)

The SURMOUNT-5 trial provides the definitive direct comparison between tirzepatide and semaglutide at their maximum weight management doses [13]. In 751 adults with obesity without diabetes over 72 weeks:

| Outcome | Tirzepatide (10-15 mg) | Semaglutide (1.7-2.4 mg) | Difference | |---|---|---|---| | Mean weight loss (%) | -20.2% | -13.7% | -6.5 pp (P value below 0.001) | | Mean absolute weight loss (kg) | -22.8 kg | -15.0 kg | -7.8 kg | | Waist circumference reduction (cm) | -18.4 cm | -13.0 cm | -5.4 cm (P value below 0.001) | | Achieved 20% or more weight loss | 47.4% | 24.2% | -- | | Achieved 25% or more weight loss | 31.6% | 16.1% | -- |

Treatment discontinuation rates were similar between groups, suggesting comparable overall tolerability at maximal doses. This trial established tirzepatide's superiority for the weight management indication with a clinically meaningful 6.5 percentage point treatment difference [13].

Tirzepatide vs Semaglutide 1 mg (Head-to-Head: SURPASS-2)

For glycemic control in type 2 diabetes, all three tirzepatide doses demonstrated superiority over semaglutide 1 mg (the approved diabetes dose at the time) for both HbA1c reduction and weight loss [2]. The tirzepatide 15 mg arm achieved -2.30% HbA1c reduction versus -1.86% with semaglutide 1 mg, with weight loss of -11.2 kg versus -5.7 kg [2].

Cross-Trial Comparisons with Liraglutide 3.0 mg

No direct head-to-head trial has compared tirzepatide with liraglutide 3.0 mg (Saxenda). However, cross-trial comparisons (acknowledging methodological limitations) suggest substantially greater efficacy for tirzepatide. Liraglutide 3.0 mg produced mean weight loss of approximately -8.0% over 56 weeks in the SCALE Obesity and Prediabetes trial (vs -2.6% placebo), compared to -15.0% to -20.9% with tirzepatide over 72 weeks in SURMOUNT-1 [9]. The difference of approximately 7 to 13 percentage points likely reflects both the dual incretin mechanism and the longer treatment duration, but the magnitude of difference exceeds what would be expected from duration alone.

Indirect Comparison with Bariatric Surgery

Cross-study comparisons with bariatric surgery outcomes are inherently limited but informative for context. Roux-en-Y gastric bypass typically produces 25-30% total body weight loss at 1-2 years, and sleeve gastrectomy produces 20-25%. Tirzepatide 15 mg (-20.9% in SURMOUNT-1; up to -26.6% with lifestyle lead-in in SURMOUNT-3) approaches the range achieved with sleeve gastrectomy [9][11]. However, weight regain after tirzepatide discontinuation (+14% over 52 weeks in SURMOUNT-4) underscores the need for chronic therapy, whereas bariatric surgery effects are more durable without ongoing treatment [12]. The choice between pharmacological and surgical approaches involves considerations of reversibility, perioperative risk, long-term durability, and patient preference.

Tirzepatide vs Retatrutide (Triple Agonist, Cross-Trial)

Retatrutide (LY3437943), a GIP/GLP-1/glucagon triple receptor agonist also developed by Eli Lilly, has now advanced to Phase 3 with results from the TRIUMPH program. In the TRIUMPH-4 trial, retatrutide at the 12 mg dose produced mean weight loss of -28.7%, and the 9 mg dose produced -26.4%, exceeding the -22.9% achieved with tirzepatide 15 mg at 176 weeks in the SURMOUNT-1 extension [26]. A network meta-analysis confirmed greater absolute and percentage weight reduction with retatrutide versus tirzepatide across available data. However, retatrutide's safety profile showed higher rates of adverse events (RR 4.10 vs 2.78 for tirzepatide), including a novel safety signal of dysesthesia reported in 8.8% (9 mg) and 20.9% (12 mg) of retatrutide-treated patients versus 0.7% with placebo. Retatrutide's additional glucagon receptor agonism may confer greater effects on hepatic lipid metabolism and energy expenditure but may also contribute to its distinct adverse event profile. Retatrutide remains investigational and is not yet FDA-approved. Head-to-head data will be needed to definitively position these agents relative to each other.

Number Needed to Treat (NNT) for Weight Loss Thresholds

Based on SURMOUNT-1 categorical weight loss data at 72 weeks (tirzepatide vs placebo) [9]:

Tirzepatide 15 mg vs placebo:

• NNT for 10% or more weight loss: approximately 1.5 (85% vs 17% achieved this threshold)
• NNT for 15% or more weight loss: approximately 1.7 (69% vs 10%)
• NNT for 20% or more weight loss: approximately 2.0 (57% vs 4%)
• NNT for 25% or more weight loss: approximately 2.9 (36% vs 1.5%)

Tirzepatide 10 mg vs placebo:

• NNT for 10% or more weight loss: approximately 1.6
• NNT for 15% or more weight loss: approximately 2.0
• NNT for 20% or more weight loss: approximately 2.7

These NNTs are exceptionally low for a chronic disease pharmacotherapy, indicating high individual-level efficacy.

Researched Applications

Type 2 Diabetes Mellitus (Strong Evidence - FDA Approved)

Tirzepatide has been extensively evaluated for glycemic control in the SURPASS clinical trial program, encompassing at least eight Phase 3 trials enrolling over 19,000 participants with type 2 diabetes across multiple comparator arms [1][2][3][4][5][6][7][8].

SURPASS-1 (monotherapy vs placebo): In 478 treatment-naive or diet-controlled adults with type 2 diabetes (baseline HbA1c ~7.9%), tirzepatide monotherapy for 40 weeks reduced HbA1c by -1.87% (5 mg), -1.89% (10 mg), and -2.07% (15 mg), compared with +0.04% for placebo [1]. Up to 92% of tirzepatide-treated participants achieved HbA1c <7%, and up to 52% achieved HbA1c <5.7% (the normoglycemic threshold). Body weight decreased by 7.0-9.5 kg with tirzepatide versus 0.7 kg with placebo [1].

SURPASS-2 (vs semaglutide 1 mg): This pivotal head-to-head trial in 1,879 adults with type 2 diabetes on metformin demonstrated that all three tirzepatide doses were noninferior and superior to semaglutide 1 mg weekly for HbA1c reduction over 40 weeks [2]. Mean HbA1c reductions were -2.01% (5 mg), -2.24% (10 mg), and -2.30% (15 mg) versus -1.86% with semaglutide 1 mg. Weight loss was also significantly greater: -7.6 to -11.2 kg with tirzepatide versus -5.7 kg with semaglutide [2].

SURPASS-3 (vs insulin degludec): In 1,444 adults on metformin with or without SGLT2 inhibitors, tirzepatide for 52 weeks produced HbA1c reductions of -1.93% to -2.37% versus -1.34% with titrated insulin degludec, with all doses achieving superiority [3]. Tirzepatide produced weight loss (-7.5 to -12.9 kg) while insulin degludec caused weight gain (+2.3 kg) [3].

SURPASS-4 (vs insulin glargine, high CV risk): In 2,002 adults with type 2 diabetes and elevated cardiovascular risk, tirzepatide achieved superior glycemic control over up to 104 weeks (pooled HbA1c reduction -2.24% vs -1.44% with insulin glargine) [4]. Importantly, adjudicated MACE-4 events were not increased with tirzepatide (HR 0.74, 95% CI 0.51-1.08), and the rate of eGFR decline was significantly slower (-1.4 vs -3.6 mL/min/1.73m2/year) [4][21].

SURPASS-5 (add-on to insulin glargine): In 475 adults on basal insulin, tirzepatide add-on therapy for 40 weeks reduced HbA1c by -2.11% to -2.40% versus -0.86% with placebo, without increased risk of clinically significant hypoglycemia [5].

SURPASS-J-mono (Japan): In Japanese patients with type 2 diabetes, tirzepatide was superior to dulaglutide 0.75 mg for glycemic control (HbA1c reduction up to -2.24%) and body weight reduction (up to -11.2 kg) over 52 weeks, with a safety profile consistent with the global trials [6].

SURPASS-AP-Combo (Asia-Pacific): In a predominantly Chinese population, tirzepatide was noninferior and superior to insulin glargine when added to metformin with or without sulfonylurea over 40 weeks, confirming cross-ethnic consistency of efficacy [7].

Chronic Weight Management (Strong Evidence - FDA Approved)

The SURMOUNT clinical trial program evaluated tirzepatide for weight management in adults with obesity or overweight, with and without type 2 diabetes [9][10][11][12][13].

SURMOUNT-1 (pivotal obesity trial without diabetes): This landmark trial enrolled 2,539 adults with obesity or overweight (without diabetes) and demonstrated mean weight reductions of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo over 72 weeks [9]. At the 15 mg dose, 36.2% achieved weight loss of >=25% and over half achieved >=20% weight loss. Waist circumference decreased by 14.6-19.9 cm with tirzepatide versus 3.4 cm with placebo [9]. These results were unprecedented for a pharmacological weight-loss intervention at the time of publication.

SURMOUNT-2 (obesity with type 2 diabetes): In 938 adults with obesity or overweight and type 2 diabetes over 72 weeks, tirzepatide produced mean weight reductions of -12.8% (10 mg) and -14.7% (15 mg) versus -3.2% with placebo [10]. Nearly half (46-49%) of tirzepatide-treated participants achieved normoglycemia (HbA1c <5.7%), with no reported cases of severe hypoglycemia [10].

SURMOUNT-3 (after intensive lifestyle intervention): In 579 adults who first achieved >=5% weight loss during a 12-week intensive lifestyle lead-in, randomization to tirzepatide produced an additional -18.4% weight loss from randomization versus +2.5% weight regain with placebo over 72 weeks, yielding total weight loss of approximately -26.6% from the start of the lead-in period [11].

SURMOUNT-4 (maintenance withdrawal study): After 36 weeks of open-label tirzepatide producing a mean -20.9% weight loss, participants randomized to continue tirzepatide lost an additional -5.5%, while those switched to placebo regained +14.0% over 52 weeks [12]. This demonstrated that continued treatment is necessary to maintain weight loss and that tirzepatide's effects are sustained with ongoing therapy.

SURMOUNT-1 Extension (176 weeks, diabetes prevention): The long-term extension of SURMOUNT-1 followed participants with obesity or overweight and prediabetes for 176 weeks (approximately 3.4 years) of continuous treatment, followed by a 17-week off-treatment period [26]. This is the longest randomized controlled tirzepatide dataset in obesity. Mean weight reductions at 176 weeks were -12.3% (5 mg), -18.7% (10 mg), and -19.7% (15 mg) versus -1.3% with placebo, demonstrating sustained efficacy over three years [26]. Crucially, progression to type 2 diabetes occurred in only 1.3% of tirzepatide-treated participants versus 13.3% with placebo (HR 0.07, 95% CI 0.0-0.1; P<0.001), representing a 93% relative risk reduction [26]. After 17 weeks off treatment, 2.4% of the tirzepatide group versus 13.7% of the placebo group had type 2 diabetes, suggesting durable metabolic benefits even after discontinuation. The safety profile over three years was consistent with shorter-term data, with gastrointestinal events occurring predominantly during the initial dose-escalation period [26].

SURMOUNT-5 (vs semaglutide, head-to-head): This first direct head-to-head comparison in 751 adults with obesity (without diabetes) showed tirzepatide's superiority over semaglutide for weight reduction at 72 weeks: mean weight loss of -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001), corresponding to mean absolute losses of 22.8 kg and 15.0 kg, respectively [13]. Waist circumference reduction was -18.4 cm versus -13.0 cm (P<0.001). A greater proportion of tirzepatide-treated participants achieved >=25% weight loss (31.6% vs 16.1%) [13].

Cardiovascular Outcomes (Strong Evidence)

SURPASS-CVOT: This definitive cardiovascular outcomes trial randomized 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide (up to 15 mg) or dulaglutide (1.5 or 4.5 mg) with a median follow-up of approximately four years [8]. The primary endpoint of MACE-3 (cardiovascular death, myocardial infarction, or stroke) occurred in 12.2% of tirzepatide-treated patients versus 13.1% of dulaglutide-treated patients (HR 0.92, 95% CI 0.83-1.01), meeting the prespecified criterion for noninferiority (P=0.003) but not superiority (P=0.09) [8]. Notably, the expanded MACE-4 endpoint (adding coronary revascularization) significantly favored tirzepatide (HR 0.88, 95% CI 0.80-0.96), and all-cause mortality was numerically lower with tirzepatide, driven primarily by reductions in non-cardiovascular death [8].

Pre-specified SURPASS meta-analysis: An earlier cardiovascular safety analysis pooling data across the SURPASS-1 through SURPASS-5 trials found no increased risk of MACE-4 with tirzepatide versus pooled comparators (HR 0.80, 95% CI 0.57-1.11) [20].

SURMOUNT-MMO (ongoing): The SURMOUNT-MMO trial is a large-scale, randomized, double-blind, event-driven cardiovascular outcomes trial designed to evaluate the impact of tirzepatide on morbidity and mortality in approximately 15,000 adults with obesity (BMI >=27 kg/m2), without diabetes, who have either established cardiovascular disease or multiple cardiovascular risk factors [29]. The primary endpoint is a five-component composite of nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, heart failure events, or death from any cause. Secondary endpoints include heart failure hospitalization, obesity-related liver outcomes, obesity-related cancers, and all-cause hospitalization [29]. SURMOUNT-MMO is notable as the first incretin-based outcomes trial to assess both primary and secondary cardiovascular disease prevention in a non-diabetic obesity population. Results are anticipated in the coming years and could fundamentally reshape the evidence base for pharmacological obesity treatment.

Heart Failure with Preserved Ejection Fraction (Strong Evidence)

SUMMIT trial: This trial randomized 731 patients with heart failure with preserved ejection fraction (EF >=50%) and obesity (BMI >=30) to tirzepatide (up to 15 mg weekly) or placebo for at least 52 weeks, with a median follow-up of 104 weeks [15]. The primary composite endpoint of cardiovascular death or worsening heart failure occurred in 9.9% of tirzepatide-treated patients versus 15.3% with placebo (HR 0.62, 95% CI 0.41-0.95; P=0.026) [15]. Worsening heart failure events alone were reduced by 46% (HR 0.54, 95% CI 0.34-0.85). Tirzepatide also improved quality of life (KCCQ-CSS: +19.5 vs +12.7), reduced systolic blood pressure (-5 mmHg treatment difference), decreased left ventricular mass (-11 g), and reduced paracardiac adipose tissue (-45 mL) in a cardiac imaging substudy [15][23].

Obstructive Sleep Apnea (Strong Evidence)

SURMOUNT-OSA: Two parallel Phase 3 trials evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea (AHI >=15 events/hour) and obesity over 52 weeks [14]. In Trial 1 (patients not using positive airway pressure), tirzepatide reduced AHI by -25.3 events/hour versus -5.3 with placebo (treatment difference -20.0; P<0.001). In Trial 2 (patients on PAP therapy), AHI decreased by -29.3 versus -5.5 events/hour (treatment difference -23.8; P<0.001) [14]. Up to 50% of tirzepatide-treated participants no longer met criteria for moderate-to-severe OSA after one year. Tirzepatide also significantly reduced hypoxic burden, hsCRP, systolic blood pressure, and improved patient-reported sleep outcomes including PROMIS Sleep-related Impairment, Sleep Disturbance, and Functional Outcomes of Sleep Questionnaire scores [14]. Based on these results, the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024, making it the first pharmacotherapy approved for this indication.

A prespecified secondary analysis of SURMOUNT-OSA published in 2025 examined cardiometabolic risk outcomes in detail [28]. Tirzepatide significantly improved multiple cardiometabolic risk factors versus placebo in both studies. Mediation analysis revealed that improvements in OSA metrics independently mediated reductions in hsCRP, HOMA-IR, and triglycerides, while combined weight loss and OSA improvement mediated systolic blood pressure reduction [28]. These findings support the concept that dual targeting of sleep-disordered breathing and obesity is required to optimize cardiometabolic benefit in this population.

Metabolic Dysfunction-Associated Steatohepatitis (Moderate Evidence)

SYNERGY-NASH: This Phase 2 trial enrolled 190 adults with biopsy-proven MASH and stage F2 or F3 liver fibrosis [16]. At 52 weeks, MASH resolution without worsening of fibrosis occurred in 44% (5 mg), 56% (10 mg), and 62% (15 mg) of tirzepatide-treated participants versus 10% with placebo [16]. Improvement of at least one fibrosis stage without MASH worsening was achieved by 51-55% of tirzepatide-treated participants versus 30% with placebo [16]. Dose-dependent reductions in aminotransferases and noninvasive markers of liver fat, inflammation, and fibrosis were observed. Phase 3 studies in MASH are ongoing.

Type 2 Diabetes Prevention (Strong Evidence)

The 176-week SURMOUNT-1 extension provided the first randomized evidence that tirzepatide can substantially reduce the incidence of new-onset type 2 diabetes in adults with obesity and prediabetes [26]. Over approximately 3.4 years, only 1.3% of tirzepatide-treated participants progressed to type 2 diabetes compared with 13.3% in the placebo group, corresponding to a hazard ratio of 0.07 (95% CI 0.0-0.1; P<0.001) — a 93% relative risk reduction [26]. This diabetes prevention effect was accompanied by sustained weight loss of up to 19.7% and improvements in fasting glucose and insulin resistance markers. Even after 17 weeks off treatment, the incidence of type 2 diabetes remained markedly lower in the tirzepatide group (2.4% vs 13.7%), suggesting durable metabolic remodeling [26]. These data position tirzepatide as a potentially transformative intervention for diabetes prevention in the high-risk population with obesity and prediabetes.

Type 1 Diabetes (Preliminary Evidence)

A Phase 2 randomized placebo-controlled trial evaluated tirzepatide in adults with type 1 diabetes and obesity (BMI >30 kg/m2) over 12 weeks [27]. Tirzepatide (escalated to 5 mg weekly) produced mean weight loss of -10.3 kg versus -0.7 kg with placebo (treatment difference -8.7 kg; P<0.0001), with 100% of tirzepatide-treated participants achieving >=5% weight loss and 45% achieving >=10% [27]. Total daily insulin dose was reduced by 35.1% versus placebo (P=0.0002), and HbA1c improved without increased hypoglycemia risk [27]. No severe adverse events were reported. These encouraging results have led to the initiation of Phase 3 trials (SURPASS-T1D-1 and SURPASS-T1D-2) to further evaluate tirzepatide as adjunctive therapy in type 1 diabetes.

Renal Outcomes (Moderate Evidence)

Post hoc analyses from the SURPASS program have demonstrated favorable renal effects. In SURPASS-4, tirzepatide was associated with significantly slower eGFR decline compared to insulin glargine (-1.4 vs -3.6 mL/min/1.73m2/year) and a 42% lower risk of a composite kidney endpoint (HR 0.58) over the extended follow-up period [21]. A pooled analysis of SURPASS-1 through SURPASS-5 showed that tirzepatide 10 mg and 15 mg were associated with significantly greater reductions in urine albumin-to-creatinine ratio (UACR) compared to comparators, with more pronounced effects in participants with baseline albuminuria (UACR >=30 mg/g) [22]. In SURPASS-CVOT, eGFR declined more slowly with tirzepatide than dulaglutide (-3.0 vs -7.2 mL/min/1.73m2/year) [8]. A prespecified post hoc analysis of SURPASS-CVOT presented at ASN Kidney Week 2025 examined patients with very high-risk CKD (defined by KDIGO 2025 criteria). Tirzepatide was associated with reduced decline in kidney function, less progression of albuminuria, and a lower risk of the composite kidney outcome compared with dulaglutide even in this vulnerable subpopulation. The investigators estimated that the magnitude of eGFR preservation could translate to delaying progression to dialysis by approximately 7-8 years. A separate analysis published in the Journal of the American Society of Nephrology (JASN) in 2025 confirmed that tirzepatide in obesity (with or without type 2 diabetes) reduced urine albumin-to-creatinine ratio after 24 weeks with sustained benefits through 72 weeks, without adversely affecting eGFR [30]. Tirzepatide has not been associated with increased risks of acute kidney injury, urinary tract infection, or nephrolithiasis [24]. Dedicated kidney outcomes trials are ongoing.

Metabolic Syndrome and Cardiometabolic Risk Factors

Beyond glucose and weight reduction, tirzepatide has been associated with improvements in multiple cardiometabolic parameters across trials, including reductions in waist circumference, systolic blood pressure, fasting triglycerides, and very-low-density lipoprotein cholesterol, as well as increases in high-density lipoprotein cholesterol [1][9]. Reductions in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, have been consistently observed across multiple trial programs [14][15]. Improvements in markers of insulin resistance have also been documented [19].

Clinical Evidence Summary

The clinical evidence base for tirzepatide is among the most extensive for any peptide therapeutic. The SURPASS program (SURPASS-1 through SURPASS-5, SURPASS-J-mono, SURPASS-AP-Combo, and SURPASS-CVOT) evaluated glycemic efficacy, cardiovascular safety, and cardiovascular outcomes in type 2 diabetes across multiple comparator arms including placebo, semaglutide 1 mg, insulin degludec, insulin glargine, and dulaglutide [1][2][3][4][5][6][7][8]. The SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, SURMOUNT-OSA, and the ongoing SURMOUNT-MMO) assessed weight-loss efficacy, long-term durability, head-to-head comparison with semaglutide, effects on obstructive sleep apnea, and diabetes prevention [9][10][11][12][13][14][26]. Additional trials have evaluated heart failure (SUMMIT) [15], liver disease (SYNERGY-NASH) [16], and type 1 diabetes (Phase 2) [27]. The SURMOUNT-MMO trial (~15,000 participants) is ongoing and will provide definitive evidence on morbidity and mortality outcomes in obesity [29].

Across all trials, tirzepatide demonstrated consistent and dose-dependent improvements in glycemic control (HbA1c reductions up to -2.37%) and body weight (reductions up to -22.5% in obesity trials, sustained at up to -19.7% over 176 weeks). Head-to-head comparisons showed superiority over semaglutide 1 mg for glycemic control (SURPASS-2) [2] and over semaglutide 2.4 mg for weight loss (SURMOUNT-5) [13]. Three-year data demonstrated a 93% reduction in the risk of type 2 diabetes in adults with obesity and prediabetes [26].

Dosing in Research

In clinical trials and in approved labeling, tirzepatide is administered once weekly by subcutaneous injection into the abdomen, thigh, or upper arm. The injection day may be changed if needed, provided there are at least 72 hours between doses.

Dose Escalation Protocol

Treatment begins at 2.5 mg once weekly for four weeks (initiation dose only; not a maintenance dose). The dose is then increased to 5 mg once weekly, with subsequent increases in 2.5 mg increments every four weeks as tolerated, through intermediate steps of 7.5 mg and 12.5 mg, to maintenance doses of 5 mg, 10 mg, or 15 mg once weekly [1][9]. The gradual escalation protocol has been shown to mitigate gastrointestinal side effects during treatment initiation.

Maintenance Doses

The three maintenance doses studied across Phase 3 trials were 5 mg, 10 mg, and 15 mg once weekly. In obesity trials, greater weight loss was generally observed with higher doses, though 5 mg also produced clinically meaningful reductions [9]. For the Zepbound (obesity) indication, 5 mg is approved as a maintenance dose; for Mounjaro (type 2 diabetes), the recommended maintenance doses are 5 mg, 10 mg, or 15 mg based on glycemic response and tolerability.

Available Formulations

Tirzepatide is supplied in single-dose prefilled pen injectors at concentrations corresponding to the six dose levels: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. In December 2024, the FDA approved a four-dose KwikPen presentation for the Zepbound indication, consolidating one month of therapy into a single device and offering an alternative to individual weekly pen injectors.

Safety and Side Effects

Gastrointestinal Effects

The most commonly reported adverse events with tirzepatide across all clinical trials are gastrointestinal, consistent with the incretin drug class. These include nausea, diarrhea, vomiting, constipation, decreased appetite, and dyspepsia [1][2][9]. Gastrointestinal side effects are generally mild to moderate in severity, occur most frequently during the dose-escalation period, and tend to diminish over time with continued treatment [9].

Pooled incidence rates across the SURMOUNT program (obesity trials):

• Nausea: 24-33% (tirzepatide) vs 6-10% (placebo)
• Diarrhea: 17-23% (tirzepatide) vs 7-9% (placebo)
• Vomiting: 8-13% (tirzepatide) vs 2-3% (placebo)
• Constipation: 11-17% (tirzepatide) vs 5-6% (placebo)
• Dyspepsia: 5-9% (tirzepatide) vs 3% (placebo)
• Abdominal pain: 5-7% (tirzepatide) vs 4% (placebo)

Pooled incidence rates across the SURPASS program (type 2 diabetes trials):

• Nausea: 12-22% (tirzepatide) vs 2-6% (comparators)
• Diarrhea: 12-17% (tirzepatide) vs 4-10% (comparators)
• Vomiting: 4-10% (tirzepatide) vs 1-4% (comparators)

Severe gastrointestinal adverse reactions were dose-dependent across SURPASS trials (5 mg: 1.7%, 10 mg: 2.5%, 15 mg: 3.1%) versus 1% with placebo. Treatment discontinuation due to adverse events ranged from 4.3% to 7.1% with tirzepatide versus 2.6% with placebo in obesity trials [9].

Thyroid C-Cell Tumors (Boxed Warning)

Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors, based on findings in 2-year rodent carcinogenicity studies. In rats, tirzepatide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell adenomas and carcinomas at clinically relevant exposures [9]. The mechanism is thought to involve sustained GLP-1 receptor activation on thyroid C-cells, leading to calcitonin release and C-cell hyperplasia progressing to neoplasia. Importantly, rodent thyroid C-cells express GLP-1 receptors at substantially higher density than human C-cells, and human calcitonin levels have not been shown to increase meaningfully with GLP-1 receptor agonist therapy in clinical studies. No confirmed cases of MTC attributable to tirzepatide have been reported in clinical trials, though post-marketing surveillance remains ongoing. Whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans has not been determined. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [9].

Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been reported in patients treated with tirzepatide and other GLP-1 receptor agonists. Adjudicated pancreatitis rates across major trial programs:

• Pooled SURMOUNT (obesity): 0.2% tirzepatide (0.14 per 100 patient-years) vs 0.2% placebo (0.15 per 100 patient-years) [9]
• Pooled SURPASS (type 2 diabetes): 0.1-0.2% tirzepatide vs 0.1% comparators, with no statistically significant difference
• SURPASS-CVOT (long-term, 4-year follow-up): Adjudicated acute pancreatitis rates were low and not significantly different between tirzepatide and dulaglutide [8]

Serum lipase and amylase elevations above the upper limit of normal are observed in approximately 20-30% of tirzepatide-treated patients but are not predictive of clinical pancreatitis. Patients should be monitored for signs and symptoms, and tirzepatide should be discontinued promptly if pancreatitis is confirmed.

Hypoglycemia

When used as monotherapy or in combination with metformin, the risk of clinically significant hypoglycemia with tirzepatide is low, consistent with the glucose-dependent nature of its insulinotropic mechanism [1][2]. However, the risk increases when combined with sulfonylureas or exogenous insulin, and dose reduction of the concomitant secretagogue or insulin may be warranted [5].

Gallbladder and Biliary Events

Cholelithiasis and cholecystitis have been reported at rates higher than placebo in tirzepatide trials. In pooled SURMOUNT data, cholelithiasis occurred in approximately 1.4% of tirzepatide-treated patients versus 0.5% with placebo, and cholecystitis in approximately 0.5% versus 0.2% [9][25]. The mechanism is multifactorial: rapid and substantial weight loss increases hepatic cholesterol secretion into bile, shifts the bile lithogenicity index, and reduces gallbladder motility (a known effect of GLP-1 receptor activation). The bile supersaturation resulting from mobilized adipose-derived cholesterol promotes gallstone nucleation. These events are consistent with observations across the GLP-1 receptor agonist class and with the gallstone risk associated with any rapid weight loss intervention, including bariatric surgery and very-low-calorie diets. Patients should be counseled about symptoms of cholelithiasis, particularly during the phase of most rapid weight reduction.

Injection Site Reactions

Injection site reactions, including erythema, pruritus, and rash, have been reported at low rates and generally mild severity [1][9].

Cardiovascular Safety

The SURPASS-CVOT trial, with over 13,000 participants and a median follow-up of four years, confirmed cardiovascular safety with no excess risk of MACE-3 compared to dulaglutide, an agent with established cardiovascular benefit [8]. The SUMMIT trial demonstrated cardiovascular benefit in patients with HFpEF and obesity [15]. No signals for increased heart rate-related adverse events have been identified in the clinical program.

Suicidal Ideation and Behavior

In response to post-marketing safety reports filed with the EMA and FDA regarding GLP-1 receptor agonists and suicidal ideation, regulatory agencies initiated investigations into this potential signal. The FDA completed a preliminary evaluation in January 2024 and found no causal association between GLP-1 receptor agonists (including tirzepatide) and suicidal ideation or behavior based on available clinical trial data and post-marketing reports. In pooled tirzepatide clinical trial data, the incidence of suicidal ideation was not elevated compared to placebo or active comparators. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) similarly concluded in 2024 that available evidence did not support a causal link, though ongoing monitoring continues. Patients with pre-existing psychiatric conditions, including depression and history of suicidal behavior, were not excluded from the major trials, though dedicated psychiatric safety studies have not been conducted.

Drug Interactions

Tirzepatide has no clinically meaningful interactions mediated through cytochrome P450 enzymes, as it is metabolized by proteolysis rather than hepatic CYP-mediated pathways [18]. However, clinically relevant interactions can occur through two mechanisms:

• Delayed gastric emptying: Tirzepatide slows gastric emptying, which can delay the absorption and reduce the peak concentration (Cmax) of co-administered oral medications. This effect is most pronounced during the dose-initiation and escalation phases. Medications with narrow therapeutic indices that depend on threshold concentrations (e.g., oral contraceptives, certain antibiotics, warfarin) may require monitoring. For oral hormonal contraceptives, patients should use an alternative non-oral contraceptive method or add a barrier method for 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation.
• Insulin and sulfonylureas: Co-administration increases hypoglycemia risk. Dose reduction of the sulfonylurea or insulin may be necessary when initiating or escalating tirzepatide [5].

No clinically significant interactions have been identified with metformin, SGLT2 inhibitors, statins, or antihypertensive agents in the clinical trial program.

Postmarketing Pharmacovigilance (FAERS Analysis)

Retrospective analyses of the FDA Adverse Event Reporting System (FAERS) covering 2022 through early 2025 identified 65,974 tirzepatide-related reports, with annual volumes increasing substantially from 3,109 (2022) to 15,776 (2023) to 37,214 (2024), reflecting expanding use [25]. Beyond the well-characterized gastrointestinal adverse events (nausea ROR 5.38; vomiting ROR 3.44), disproportionality analyses detected signals for eructation (ROR 46.56), gastroesophageal reflux disease (ROR 3.24), injection site hemorrhage (ROR 27.8), and increased blood glucose (ROR 6.22) [25]. A total of 144 adverse event signals across 17 system organ classes were identified, including musculoskeletal complaints and metabolic disorders. While FAERS analyses are hypothesis-generating and subject to reporting biases, these data reinforce the importance of ongoing postmarketing surveillance as the treated population expands beyond the demographics of the original clinical trials.

Other Safety Considerations

Diabetic retinopathy complications have been monitored across trials, consistent with GLP-1 receptor agonist class surveillance. Rapid improvements in glycemic control may theoretically worsen pre-existing retinopathy in patients with diabetes. Renal safety has been favorable across all studied populations [21][22][24][30].

Comparison with Semaglutide

Tirzepatide and semaglutide represent the two leading incretin-based therapies and have been directly compared in two landmark trials:

SURPASS-2 (Type 2 Diabetes): All three tirzepatide doses (5, 10, and 15 mg) were superior to semaglutide 1 mg for HbA1c reduction (-2.01% to -2.30% vs -1.86%) and weight loss (-7.6 to -11.2 kg vs -5.7 kg) in adults with type 2 diabetes [2]. A limitation is that semaglutide was used at the 1 mg dose (approved for diabetes), not the 2.4 mg dose used for weight management.

SURMOUNT-5 (Obesity): The first head-to-head comparison at maximum tolerated doses for weight management showed tirzepatide's superiority: -20.2% versus -13.7% weight loss at 72 weeks (P<0.001), with greater reductions in waist circumference and a higher proportion achieving >=25% body weight loss [13].

Key structural and pharmacological differences between the two molecules include tirzepatide's dual GIP/GLP-1 mechanism (vs GLP-1-only for semaglutide), its GIP-based peptide backbone (vs GLP-1-based for semaglutide), C20 fatty diacid (vs C18 for semaglutide), shorter half-life (~5 days vs ~7 days), and larger molecular weight (~4813 Da vs ~4114 Da) [17][18].

Regulatory Status

Tirzepatide has received regulatory approval in multiple jurisdictions:

• United States: FDA-approved as Mounjaro for type 2 diabetes (May 13, 2022) and as Zepbound for chronic weight management in adults with BMI >=30 kg/m2, or BMI >=27 kg/m2 with at least one weight-related comorbidity (November 8, 2023). In December 2024, the FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA results, making it the first pharmacotherapy approved for OSA [14]. Also in December 2024, the FDA approved a four-dose monthly KwikPen presentation for the Zepbound weight management indication.
• European Union: Approved by the European Medicines Agency (EMA) as Mounjaro for type 2 diabetes (September 2023) and for chronic weight management in adults with obesity or overweight with at least one weight-related condition (June 2024). In December 2025, the CHMP adopted a positive opinion recommending extension of the Mounjaro type 2 diabetes indication to adolescents and children from 10 years of age. The EMA also authorized a KwikPen presentation for both indications.
• Japan: Approved for type 2 diabetes based on the SURPASS-J program.
• Other markets: Approvals or regulatory reviews have occurred in the United Kingdom, Australia, Canada, and additional countries. The European Association for the Study of Obesity (EASO) published a 2025 pharmacotherapy framework positioning tirzepatide and semaglutide as first-line treatments for obesity, based on evidence of >=15% weight loss and benefits in cardiovascular disease and sleep apnea.

Available formulations include single-dose prefilled pen injectors at 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. A four-dose KwikPen (monthly) formulation is available for the Zepbound indication in the United States. No oral formulation of tirzepatide is currently approved or in advanced clinical development; Eli Lilly's oral incretin program focuses on orforglipron, a non-peptide small molecule GLP-1 receptor agonist.

Related Peptides

Tirzepatide is pharmacologically related to the GLP-1 receptor agonist class, which includes semaglutide, liraglutide, dulaglutide, and exenatide. It is distinguished by its additional GIP receptor agonist activity, making it the first approved dual incretin agonist. It is also structurally distinct in being based on the GIP sequence rather than the GLP-1 sequence. Head-to-head data from SURPASS-2 and SURMOUNT-5 demonstrate that tirzepatide offers greater glycemic and weight-loss efficacy compared to semaglutide [2][13]. Emerging agents in the multi-incretin space include triple agonists (GIP/GLP-1/glucagon receptor agonists such as retatrutide), which are currently in Phase 3 clinical development.

See also: Semaglutide, Liraglutide

References

1. [1] Rosenstock J, Wysham C, Frias JP, et al. (2021). Efficacy and safety of once-weekly tirzepatide monotherapy versus placebo in patients with type 2 diabetes (SURPASS-1). Lancet. DOI
2. [2] Frias JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. DOI
3. [3] Ludvik B, Giorgino F, Jodar E, et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin in patients with type 2 diabetes (SURPASS-3). Lancet. DOI
4. [4] Del Prato S, Kahn SE, Pavo I, et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. DOI
5. [5] Dahl D, Onishi Y, Norwood P, et al. (2022). Tirzepatide as add-on to insulin glargine in type 2 diabetes (SURPASS-5). JAMA. DOI
6. [6] Inagaki N, Takeuchi M, Oura T, et al. (2022). Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono). Lancet Diabetes & Endocrinology. DOI
7. [7] Gao L, Lee BW, Chawla M, et al. (2023). Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nature Medicine. DOI
8. [8] Nicholls SJ, Bhatt DL, Buse JB, et al. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). New England Journal of Medicine. DOI
9. [9] Jastreboff AM, Aroda VR, Ahmann A, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. DOI
10. [10] Garvey WT, Frias JP, Jastreboff AM, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. DOI
11. [11] Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nature Medicine. DOI
12. [12] Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. DOI
13. [13] Aronne LJ, Sattar N, Horn DB, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. DOI
14. [14] Malhotra A, Grunstein RR, Engstrom Falkenberg F, et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. DOI
15. [15] Packer M, Zile MR, Kramer CM, et al. (2024). Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine. DOI
16. [16] Loomba R, Hartman ML, Lawitz EJ, et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. New England Journal of Medicine. DOI
17. [17] Nauck MA, D'Alessio DA. (2018). GIP and GLP-1 as incretin hormones: lessons from single and dual agonists. Journal of Clinical Endocrinology & Metabolism. DOI
18. [18] Willard FS, Douros JD, Gabe MBN, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. DOI
19. [19] Thomas MK, Nikooienejad A, Bray R, et al. (2021). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Investigation. DOI
20. [20] Sattar N, McGuire DK, Pavo I, et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis (SURPASS program). Nature Medicine. DOI
21. [21] Heerspink HJL, Sattar N, Pavo I, et al. (2022). Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. Lancet Diabetes & Endocrinology. DOI
22. [22] Heerspink HJL, Apperloo H, Davies MJ, et al. (2025). Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the SURPASS-1-5 clinical trials. Diabetes Care. DOI
23. [23] Packer M, Butler J, Zile MR, et al. (2025). Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nature Medicine. DOI
24. [24] Heerspink HJL, Cherney DZI. (2023). Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal. DOI
25. [25] Various (2025). Real-world safety concerns of tirzepatide: a retrospective analysis of FAERS data (2022-2025). PMC.
26. [26] Jastreboff AM, Aroda VR, Ahmann A, et al. (2025). Tirzepatide for obesity treatment and diabetes prevention. New England Journal of Medicine. DOI
27. [27] Garg SK, Engel SS, Engel SS, et al. (2025). Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial. Diabetes Care. DOI
28. [28] Malhotra A, Grunstein RR, et al. (2025). Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nature Medicine. DOI
29. [29] Lam CSP, et al. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity. DOI
30. [30] Heerspink HJL, et al. (2025). Kidney parameters with tirzepatide in obesity with or without type 2 diabetes. Journal of the American Society of Nephrology.